First Author: S.F.Aki TURKEY
Co Author(s): A. Altun A.K. Arsan H.K. Kokcen S.A. Kurna 0 0 0 0 0 0 0 0 0
Back to previous
To compare effectiveness of intravitreal bevacizumab and dexamethasone implant in retinal vein occlusion (RVO) by measuring best corrected visual acuity (BCVA) and central macular thickness (CMT).
Randomised and prospective study
Thirty eye of 30 patients received the diagnosis of RVO in our clinic included in to this study. The patients randomly divided into 2 groups. Fifteen eyes in Group 1 received 1.25 mg intravitreal bevacizumab (Avastin). Fifteen eyes in Group 2 received 0.7 mg intravitreal dexamethasone implant (Ozurdex). All cases followed up at least 115 days, at first and third months. At each visit BCVA, CMT and intraocular pressure of the cases recorded by one physician. Results compared by using SPSS 17.0 programme.
BCVA improved significantly in both groups at first and third months when compared to the beginning (p<0.05), but there was no statistically significant difference between the groups (p=0.687, p=0.837). CMT improved significantly in both groups at first and third months when compared to the beginning (p<0.05), but there was no statistically significant difference between the groups (p=0.275, p=0.462).
Intravitreal bevacizumab and dexamethasone implant look like to be effective treatment options of macular edema due to retinal vein occlusion. In short term (3 months) there might be no statistically significant difference between them. Long term and expanded studies are needed to comfirm these results.